This week: CagriSema's Phase 3 reality check
New Research Brief is up: CagriSema and the Two Hormone Bet. The short version: CagriSema pairs cagrilintide (a long acting amylin analog) with semaglutide (a GLP 1) in one weekly…
Peptide research intelligence
Peptide research,
graded.
Every peptide claim you’ve seen online, checked against the actual studies — graded A to D, with what’s known, what isn’t, and a community that challenges hype with sources.
Try:
Educational use only. No dosing, treatment, or individualized medical guidance.
From the library
ARelatively Stronger Human Evidence
Evidence grade A — Relatively Stronger Human EvidenceSemaglutide
FDA-ApprovedMetabolic · Body Composition
Semaglutide is a once-weekly (or oral daily) GLP-1 receptor agonist with a very large Phase 3 evidence base.
Open the report32
compounds graded A–D
113
cited studies & sources
12
sections in every report
0
dosing protocols. Ever.
Claim check
The internet says one thing. The studies say another.
Pick a claim. We stamp it with the evidence grade from the full research report — and show you why.
The claim you’ve seen
“BPC-157 heals torn tendons in a few weeks.”
EvidenceD
What the research shows · Mostly Preclinical
Hundreds of rodent studies — but the few human trials are small, date from the late '90s and 2000s, and studied bowel disease, not tendons.
The landscape
All 32 compounds, one honest scale.
22 of 32 sit in C or D — mostly small or animal studies. That's the real state of peptide research, and we show exactly where each compound lands.
32 compounds
Relatively Stronger Human Evidence
5 compounds
Early but Meaningful Human Evidence
5 compounds
Mixed or Limited Human Evidence
13 compounds
Mostly Preclinical
9 compounds
Hover or tab through a compound to preview it. Grades describe research maturity — not safety, quality, or suitability.
Inside a report
Twelve sections. Zero hype.
Every report separates what studies found from what people claim, spells out the limitations, and cites its sources. The grade and key takeaways are free. The rest is Vial+.
Mechanism explained in plain language
What human vs. animal studies actually show
Limitations, open questions, and safety signals
Regulatory status and every cited source
thevialtheory.com/compound/bpc-157
Healing · Gut · Musculoskeletal
BPC-157
A 15-amino-acid synthetic peptide fragment derived from a gastric juice protein, widely promoted for soft-tissue healing despite an evidence base dominated by rodent studies.
DMostly Preclinical
Evidence grade D — Mostly PreclinicalKey takeawaysFree
- ›BPC-157 is a synthetic peptide based on a fragment of a protein found in gastric (stomach) fluid.
- ›Most of the evidence comes from animal and laboratory studies; human trials are limited and mostly date from the late 1990s and early 2000s.
- ›It is widely discussed online for healing and recovery, but those claims go well beyond what current human research supports.
What it is
BPC-157 is a synthetic 15-amino-acid peptide whose sequence corresponds to a partial fragment of a larger protein identified in human gastric juice in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. The 'BPC' designation stands for 'Body Protection Compound,' a name applied to the parent gastric protein based on observations of its broad cytoprotective effects in early rodent models.
How it works
Current research + reference timeline
Potential benefits being studied
Limitations and unknowns
Safety considerations
Regulatory status
Sources (4 cited)
The Lab · free community
Where claims get challenged.
Post a Theory, attach a source, and let the community back it or push back. Discussion is free and open.
Signal
Back posts that bring real sources and careful reasoning.
Challenge
Flag claims that need better evidence — politely, with a reason.
Vial Score
Credibility earned through sourced contributions, not follower counts.
Theory DebatesQuestion
Debate — does adding amylin meaningfully beat GLP-1 alone?
Here's a clean one to argue with evidence, not vibes. Claim: adding an amylin analog (cagrilintide) on top of a GLP 1 (semaglutide) produces meaningfully more benefit than the GLP…
Beginner QuestionsQuestion
New here? Three questions to ask about any peptide claim
If you're just getting into peptides, these three questions filter out most of the hype: 1. Is it human evidence? A result in mice is a hypothesis, not proof. Compounds with only a…
Research briefs
What's moving in peptide science.
New briefs, in your inbox
Join the list for new Research Briefs and notable evidence-grade changes.
Pricing
Free to explore. $20 to go deep.
The grades, the map, and the community are free. Vial+ is a one-time unlock for every full report and brief.
Free
$0
- Evidence grade + key takeaways for every compound
- The Lab community — post, discuss, challenge
- Library search, topic explorer, and the evidence map
- Research Brief openings
Vial+
$20one-time · lifetime access
- Full 12-section research report for every compound
- Evidence gauges, reference timelines, compare radars
- Every Research Brief in full, plus the archive
- Cited sources with one-click export
Check the grade before you believe the hype.
Try: